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Abstract
The stimulant designer drug 3,4-methylenedioxypyrovalerone (MDPV) was ﬁrst
synthesized by Boehringer Ingelheim in 1969 and introduced on the black market
in 2006. Only a small number of fatal intoxication cases have been reported in
the literature, all with signiﬁcant blood MDPV concentrations. In this report,
we describe one fatality attributed to an idiosyncratic reaction to MDPV. The
victim displayed agitation, violent behavior and delirium followed by cardiac
arrest. Hyperthermia was observed at the hospital. The MDPV cardiac and
femoral blood concentrations were 6 ng/mL. The presence of excited delirium
syndrome and MDPV, a drug with a pharmacology similar to cocaine, leads to
the conclusion that the victim suﬀered a fatal adverse reaction to MDPV. This
is the ﬁrst published case of idiosyncratic reaction to MDPV.
1. Introduction
In order to circumvent existing legislation on controlled substances, deriva-
tives of known psychoactive substances began to appear on the black market as
“designer drugs” in the mid-2000s [1, 2]. One popular family of designer drugs
are the synthetic cathinones or “bath salts”. 3,4-methylenedioxypyrovalerone
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(MDPV) is a member of this family: a β-keto phenylalkylamine, derivative of
the natural alkaloid cathinone found in the plant Catha edulis (khat) [1, 3].
MDPV, initially synthesized by Boehringer Ingelheim in 1969 [1], was ﬁrst de-
tected in Japan in 2006, and subsequently was increasingly found throughout the
world [4, 5]. In 2011, the Drug Enforcement Agency of the United States (DEA)
scheduled MDPV on a temporary emergency basis [6, 7]. Since this time, the
prevalence of MDPV in synthetic cathinones decreased in favor of unregulated
compounds.
Synthetic cathinones are stimulants consumed for the eﬀects of increased
alertness and energy, euphoria, excitement, improved mood, sociability and in-
tensiﬁcation of sensory experience (mild empathogenic eﬀects) [5]. Undesired
cardiac and neurological eﬀects include tachycardia, hypertension, cardiac ar-
rest, agitation, aggressive and combative behavior, disorientation, confusion and
paranoia [1, 5, 6, 7, 8, 9, 10].
The physical form of MDPV is a white, tan, gray, yellow or brown odorless
powder [1, 6] and is often mixed with caﬀeine and lidocaine or benzocaine [5].
It is marketed as “bath salt” (in the US) or “plant feeder” (in Europe) and sold
under 50 diﬀerent known brand names on the Internet or in head shops, con-
venience stores, gas stations and tobacco shops [5, 6, 11, 12]. Its main modes
of ingestion are oral, intravenous, insuﬄation (snorting) and inhalation (smok-
ing) [1, 5, 6, 8, 13, 14, 15]. Doses of 5 to 30 mg in a single ingestion are typi-
cal [1, 5, 8], with eﬀects lasting 1 to 3 h [10].
Although several clinical cases of consumption of, or intoxication by, MDPV
have been reported [4, 9, 12, 13, 15, 16, 17, 18, 19, 20, 21], there are only a few fatal
MDPV intoxication cases published with toxicology results [3, 6, 10, 14, 22, 23].
In all of these cases, the MDPV concentration was elevated (> 80 ng/mL in
whole blood). We present here a case of fatal idiosyncratic reaction to MDPV,




The victim was a 42 year old Native American male that had been incarcer-
ated for several months prior to the event. In the early afternoon, the man was
standing in front of his cell, talking incoherently. He then approached the guards’
post and became hysterical and disorganized. Prison personnel attempted to
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physically control him, but he fought them vigorously. He was eventually cuﬀed
at the wrists and ankles and put into a padded cell, lying on his side. 27 minutes
later, the man was in cardiorespiratory arrest and resuscitation maneuvers were
started. Upon arrival at the hospital, 1h19 into the event, the victim’s rectal
temperature was 39.3 ◦C. His death was pronounced 1h40 after the beginning of
the event. Since the victim was in cardiac arrest upon arrival at the hospital, no
biochemistry or toxicology screen was performed.
2.2. Autopsy ﬁndings
The deceased was 182 cm tall and weighed 156 kg. The external exam re-
vealed the presence of linear abrasions and light bruises at the wrists and ankles,
most likely due to the cuﬀs placed on the victim. Also, numerous bruises were
observed on the four limbs, which could have resulted from conﬁnement of the
victim by the prison personnel or have been auto-inﬂicted. A linear abrasion
on the shoulder blade and abrasions on the knees were also observed. No other
signiﬁcant traumatic lesions were apparent on external examination.
The internal exam revealed the presence of left pleural adhesions. The heart
weighed 520 g and revealed a slight left ventricle hypertrophy, without any con-
genital anomaly, valvular or coronary disease. The lungs (right 820 g, left 870 g)
were heavy and congested, which was conﬁrmed through histological analysis.
The liver weighed 1780 g and was aﬀected by steatosis without associated cir-
rhosis, which was also conﬁrmed by the histological exam. The urinary bladder
contained 80 mL of urine. The full length of the gastro-intestinal tract was
opened and no intra-luminal body was found. Gastric contents (60 mL) were a
brownish liquid with beige, black and green particles. Rib fractures attributed to
CPR were observed. No cranial, spine, hip or limb fractures were seen. No other
anatomic lesions were observed.
2.3. Toxicological analysis
Peripheral blood from the femoral vein, cardiac blood (pooled from both
ventricles), urine, gastric contents and vitreous humor were recovered for toxi-
cological analyses. Toxicology included cyanide screening, ethanol and volatile
compound determination, immunological screening (cocaine, opiates, PCP, am-
phetamines, cannabinoids, barbiturates, salicylates, benzodiazepines, acetamino-
phen, paracetamol and methadone) as well as gas-chromatography-mass spec-
trometry (GC-MS-NPD) screening and liquid chromatography-tandemmass spec-
trometry (LC-MS/MS) quantiﬁcation. All of these methods (unpublished) are
validated, and the quantitative methods are accredited under ISO 17025/CAN-P
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1578 standards. To carry out the LC-MS/MS analysis, all matrices were ex-
tracted with a protein precipitation protocol using a mixture of acetonitrile and
acetone as the precipitating agent. Results of the toxicological investigation are
shown in Table 1.
Table 1: Postmortem toxicological analysis results
Also detected in cardiac blood, femoral blood and urine were the metabolites
demethylenyl-methyl-MDPV, N-desmethylmirtazapine and THC-COOH glucuro-
nide. According to medical records, the victim had a prescription for mirtazapine
and clonazepam, explaining the presence of these two compounds in the toxicol-
ogy results.
By taking into account circumstances surrounding death (agitation, violent
behavior, hyperthermia) and toxicology results, the cause of death was ruled to
be complications of an adverse reaction to consumption of MDPV by the victim.
It was also noted that the pre-existing medical condition of the victim (obesity,
slight cardiac hypertrophy) may have contributed to death.
Subsequent toxicological screening by liquid chromatography-time of ﬂight
mass spectrometry (LC-QToF) initially suggested the presence of 4-acetoxy-DMT
(4-AcO-DMT) in cardiac blood and urine via a library hit. 4-acetoxy-DMT (also
known as psilacetin and O-acetylpsilocin) is a synthetic pro-drug of the hallucino-
genic compound psilocin [24]. However, further analysis using reference material




A certain number of MDPV intoxication cases have already been published
in the literature (see Table 2). In all published reports, the MDPV concentration
in blood is more elevated than what was observed in the case presented here. In-
deed, all but one case show MDPV concentrations at least 10 times higher than
the 6 ng/mL found in the cardiac and femoral blood of the victim. Although
an MDPV overdose (in the strictest sense of the term) seems unlikely here, an
adverse reaction to MDPV is a probable mechanism of death.
MDPV is a dopamine and norepinephrine reuptake inhibitor acting as a stim-
ulant [1, 7, 9, 22]. In vitro transporter assays performed on brain synaptosomes
show that MDPV functions as a monoamine uptake pure blocker (like cocaine)
and not as a monoamine transporter substrate (like amphetamine) [25]. The
pharmacology of MDPV is thus closer to cocaine than MDMA, as was previously
thought.
It is well known that there is no “safe” concentration for cocaine, since virtu-
ally any concentration can trigger an adverse reaction and ultimately death [26].
Given the similarity between the pharmacology of MDPV and cocaine, it would
seem logical that a similar potential for adverse reactions exists with MDPV.
Stimulant drug use, particularly cocaine, is a known trigger of excited delirium
syndrome (ExDS), even at recreational dosages [27]. Excited delirium syndrome
is characterized by an excited or agitated state, delirium, sometimes comple-
mented by tachycardia and hyperthermia followed by cardiac arrest [3, 27]. The
behavior reported by prison personnel as well as the hyperthermia highlighted at
the hospital both ﬁt the ExDS proﬁle. The exact mechanism of this potentially
lethal side eﬀect is unknown. The observed hyperthermia is thought to result
from dysregulation of the dopaminergic pathways in the hypothalamus [3] and
has been reported in an elevated number of MDPV intoxications and adverse
reactions [3, 4, 6, 9, 16, 17, 23]. The presence of ExDS adds to the proﬁle of an
adverse reaction to a stimulant. It is worth noting that the presence of mirtazap-
ine, even at therapeutic concentrations, might have contributed to the elevation
of serotonin levels and thus the reported agitation of the victim.
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Table 2: Previously published MDPV fatal intoxications
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Demethylenyl-methyl-MDPV (also called methyl cathecol pyrovalerone [2])
has been previously identiﬁed in studies of in vitro human liver microsomes and
in vivo rat MDPV metabolism [2, 28]. It is hypothesized to result from the methy-
lation of the initial demethylenyl-MDPV metabolite produced by CYP 1A2,
CYP 2C19 and CYP 2D6 [28] enzymes. The lack of additional metabolite stan-
dards limited LC-MS/MS analysis for identiﬁcation and quantiﬁcation of other
metabolites besides demethylenyl-methyl-MDPV in the matrices.
In the case reported here, several elements point towards a case of fatal id-
iosyncratic reaction to the stimulant designer drug MDPV, such as excited delir-
ium syndrome with hyperthermia, low concentrations of MDPV in blood and
the similarity of the pharmacology of MDPV with cocaine. This is a category of
MDPV intoxication previously unreported in the literature.
4. Key points
1. 3,4-methylenedioxypyrovalerone (MDPV) is a stimulant designer drug with
a pharmacology similar to cocaine.
2. Excited delirium syndrome (ExDS) is characterized by agitation, delirium,
tachycardia and hyperthermia. A common trigger is stimulant drug con-
sumption.
3. Presence of ExDS with recreational MDPV concentrations should be con-
sidered as indications of a potential adverse reaction to MDPV.
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